Evidence map›Paper›PMID 42564627›Full record

ArticleFrontiers in neurology

GMANet: a CPU-only ultra-lightweight 3D CNN for real-time glioma triage in resource-limited environments.

Caijian Hua, Xuerong Jing, Liuying Li, Xia Zhou

Abstract read
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caijian HuaSchool of Computer Science, Sichuan University of Science and Engineering, Zigong, China.
Xuerong JingSchool of Computer Science, Sichuan University of Science and Engineering, Zigong, China.
Liuying LiTraditional Chinese Medicine Department, Zigong First People's Hospital, Zigong, China.
Xia ZhouTraditional Chinese Medicine Department, Zigong First People's Hospital, Zigong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Unlike our previously published Graphics Processing Unit-based (GPU) Dynamic Pathway-Enhanced Attention Network (DPEA-Net) which is optimized for radiotherapy planning, state-of-the-art GPU-dependent brain tumor segmentation models cannot be deployed in primary care clinics, community hospitals, or intraoperative Magnetic Resonance Imaging (MRI) settings where dedicated GPU hardware is unavailable. This hardware barrier leads to delayed detection, missed urgent referrals, and prolonged triage in resource-limited environments. Existing lightweight models still suffer from slow Central Processing Unit (CPU) inference and inadequate boundary quality for rapid clinical decision-making. Methods: We propose Gated Multi-scale Attention Network (GMANet), an ultra-lightweight 0.20M-parameter 3D CNN explicitly engineered for CPU-only real-time glioma triage. To achieve extreme deployability under strict computational constraints, we introduce three synergistic modules: a gated multi-scale dilated (GMSD) block for efficient multi-scale feature extraction, a full-dimension attention (FDA) module for 3D anatomical continuity, and a learnable transposed upsampling (LTU) module for CPU-optimized boundary recovery. The moderate reduction in enhancing tumor (ET) precision represents a deliberate trade-off to prioritize rapid whole tumor (WT) and tumor core (TC) assessment for initial screening. Results: On BraTS2019 and BraTS2021, GMANet achieves WT Dice of 92.45% and 90.93%, TC Dice of 86.28% and 84.72%, and ET Dice of 78.42% and 76.68%, respectively, with only 20.10 Giga Floating-Point Operations (GFLOP). On a standard laptop CPU, inference time is 8.49 s per volume.The ET Dice exceeds the commonly adopted threshold for brain tumor preliminary screening in research practice. This performance renders the model potentially applicable to preliminary triage, pending further prospective clinical validation. Conclusion: GMANet trades marginal ET precision for extreme CPU deployability and sub-10-second inference, acting as a potential complementary tool to our GPU-based DPEA-Net. GMANet is designed to support a two-stage clinical pathway: fast CPU screening followed by GPU precision assessment, which requires further implementation and clinical evaluation. Importantly, GMANet is not an incremental improvement of our previously published GPU-based DPEA-Net but a complementary model targeting a distinct clinical scenario where GPUs are unavailable.

Indexed as

brain tumor segmentationclinical triagecomplementary to GPU-based modelsCPU-only inferenceresource-limited settingsultra-lightweight 3D CNN

Identifiers

PMID42564627
PMCPMC13445960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.